ARCAGEN matches targeted treatment to almost half of rare tumor types

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Oct 22 / Springer Healthcare

ARCAGEN matches targeted treatment to almost half of rare tumor types

Oncology Solid Tumours Pan-tumour ESMO-2023

Description

Marie Morfouace and Jean-Yves Blay discuss initial ARCAGEN study findings showing that almost half of patients with cancers of unknown primary and other rare tumours can be matched to a molecularly targeted therapy.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.